Fairmount Funds Management LLC 13D and 13G filings for Spyre Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-04-25 4:40 pm Purchase | 2024-04-23 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 4,508,579 11.170% | 3,672,120 (+439.01%) | Filing |
| 2023-12-29 5:00 pm Sale | 2023-12-29 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 836,459 2.320% | -2,977,442 (-78.07%) | Filing |
| 2023-12-11 5:21 pm Unchanged | 2023-12-07 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 10.590% | 0 (Unchanged) | Filing |
| 2023-11-29 5:08 pm Purchase | 2023-11-24 | 13D | Spyre Therapeutics, Inc. SYRE | Fairmount Funds Management LLC | 3,813,901 12.700% | 3,813,901 (New Position) | Filing |